These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 32110946)

  • 21. Genomic and tumour microenvironmental biomarkers of immune checkpoint inhibitor response in advanced Taiwanese melanoma.
    Chang JW; Huang CJ; Huang WK; Wang YC; Hsieh JJ; Chang YY; Huang YL; Wu CL; Wang YH; Chen SJ; Tan KT; Chen CP; Wu CE
    Clin Transl Immunology; 2023; 12(8):e1465. PubMed ID: 37649975
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Primary anorectal melanoma: clinical, immunohistology and DNA analysis of 43 cases.
    Dodds TJ; Wilmott JS; Jackett LA; Lo SN; Long GV; Thompson JF; Scolyer RA
    Pathology; 2019 Jan; 51(1):39-45. PubMed ID: 30497801
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BRAF inhibitors: efficacious and tolerable in BRAF-mutant acral and mucosal melanoma.
    Bai X; Mao LL; Chi ZH; Sheng XN; Cui CL; Kong Y; Dai J; Wang X; Li SM; Tang BX; Lian B; Zhou L; Yan XQ; Guo J; Si L
    Neoplasma; 2017; 64(4):626-632. PubMed ID: 28485171
    [TBL] [Abstract][Full Text] [Related]  

  • 24. JAK2, PD-L1, and PD-L2 (9p24.1) amplification in metastatic mucosal and cutaneous melanomas with durable response to immunotherapy.
    Gupta S; Vanderbilt CM; Cotzia P; Arias Stella JA; Chang JC; Chen Y; Tang LH; DeLair DF; Yao J; Ladanyi M; Ross DS
    Hum Pathol; 2019 Jun; 88():87-91. PubMed ID: 30236595
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma.
    Bol KF; Ellebaek E; Hoejberg L; Bagger MM; Larsen MS; Klausen TW; Køhler UH; Schmidt H; Bastholt L; Kiilgaard JF; Donia M; Svane IM
    Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31623302
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of combined radiotherapy and anti-programmed death 1 therapy in acral and mucosal melanoma.
    Kato J; Hida T; Someya M; Sato S; Sawada M; Horimoto K; Fujioka M; Minowa T; Matsui Y; Tsuchiya T; Kitagawa M; Nakata K; Sakata KI; Torigoe T; Uhara H
    J Dermatol; 2019 Apr; 46(4):328-333. PubMed ID: 30758859
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
    Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ
    Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of Radiotherapy Combined With Pembrolizumab on Local Tumor Control in Mucosal Melanoma Patients.
    Kim HJ; Chang JS; Roh MR; Oh BH; Chung KY; Shin SJ; Koom WS
    Front Oncol; 2019; 9():835. PubMed ID: 31552171
    [No Abstract]   [Full Text] [Related]  

  • 29. Hyperprogression and Immunotherapy: Fact, Fiction, or Alternative Fact?
    Adashek JJ; Subbiah IM; Matos I; Garralda E; Menta AK; Ganeshan DM; Subbiah V
    Trends Cancer; 2020 Mar; 6(3):181-191. PubMed ID: 32101722
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PD-L1 expression in tumour-infiltrating lymphocytes is a poor prognostic factor for primary acral melanoma patients.
    Ren M; Dai B; Kong YY; Lv JJ; Cai X
    Histopathology; 2018 Sep; 73(3):386-396. PubMed ID: 29637587
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hyperprogression after one dose of nivolumab in sinonasal cancer: A case report.
    Xiang JJ; Uy NF; Minja FJ; Verter EE; Burtness BA
    Laryngoscope; 2020 Apr; 130(4):907-910. PubMed ID: 31058321
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hyperprogression of a mismatch repair-deficient colon cancer in a humanized mouse model following administration of immune checkpoint inhibitor pembrolizumab.
    Sahin I; George A; Zhang S; Huntington KE; Ordulu Z; Zhou L; El-Deiry WS
    Oncotarget; 2021 Oct; 12(21):2131-2146. PubMed ID: 34676046
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of BRAF Inhibitors in Asian Metastatic Melanoma Patients: Potential Implications of Genomic Sequencing in BRAF-Mutated Melanoma.
    Kim HK; Lee S; Kim K; Heo MH; Lee H; Cho J; Kim NKD; Park W; Lee SJ; Kim JH; Jang KT; Choi SH; Lee J
    Transl Oncol; 2016 Dec; 9(6):557-564. PubMed ID: 27883956
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genomic aberrations of MDM2, MDM4, FGFR1 and FGFR3 are associated with poor outcome in patients with salivary gland cancer.
    Ach T; Schwarz-Furlan S; Ach S; Agaimy A; Gerken M; Rohrmeier C; Zenk J; Iro H; Brockhoff G; Ettl T
    J Oral Pathol Med; 2016 Aug; 45(7):500-9. PubMed ID: 26661925
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biomarkers, measured during therapy, for response of melanoma patients to immune checkpoint inhibitors: a systematic review.
    Ouwerkerk W; van den Berg M; van der Niet S; Limpens J; Luiten RM
    Melanoma Res; 2019 Oct; 29(5):453-464. PubMed ID: 30855527
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients.
    Tang B; Yan X; Sheng X; Si L; Cui C; Kong Y; Mao L; Lian B; Bai X; Wang X; Li S; Zhou L; Yu J; Dai J; Wang K; Hu J; Dong L; Song H; Wu H; Feng H; Yao S; Chi Z; Guo J
    J Hematol Oncol; 2019 Jan; 12(1):7. PubMed ID: 30642373
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High GILT Expression Is Associated with Improved Survival in Metastatic Melanoma Patients Treated with Immune Checkpoint Inhibition.
    Adams AC; Borden ES; Macy AM; Thomson N; Cui H; Gimbel MI; Wilson MA; Buetow KH; Roe DJ; DiCaudo DJ; Homsi J; Hastings KT
    Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565329
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy.
    Gatalica Z; Xiu J; Swensen J; Vranic S
    Eur J Cancer; 2018 May; 94():179-186. PubMed ID: 29571084
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hyperprogression after immunotherapy: A comprehensive review.
    Okan Cakir M; Kirca O; Gunduz S; Ozdogan M
    J BUON; 2019; 24(6):2232-2241. PubMed ID: 31983088
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma.
    Buchbinder EI; Sosman JA; Lawrence DP; McDermott DF; Ramaiya NH; Van den Abbeele AD; Linette GP; Giobbie-Hurder A; Hodi FS
    Cancer; 2015 Nov; 121(22):4007-15. PubMed ID: 26264378
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.